Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Abstract Background Epigenetic modulators may sensitize platinum-resistant ovarian cancer (PROC) to immune checkpoint inhibition by reprogramming the tumor microenvironment. Methods We report clinical and translational findings from a phase II non-randomized study of pembrolizumab and oral azacitidi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Blair V. Landon, Julia L. Boland, Andrea E. Wahner Hendrickson, Deborah K. Armstrong, Boris Winterhoff, Jaime Wehr, Akshaya V. Annapragada, Christopher Cherry, Archana Balan, Guneet Kaleka, Victor E. Velculescu, Stephen B. Baylin, Cynthia A. Zahnow, Dennis J. Slamon, Gottfried E. Konecny, Valsamo Anagnostou, John A. Glaspy
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-02-01
Col·lecció:	Communications Medicine
Accés en línia:	https://doi.org/10.1038/s43856-026-01404-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!